Evidence map›Paper›PMID 40791493›Full record

ArticlebioRxiv : the preprint server for biology2025

Enabling Organ- and Injury-Specific Nanocarrier Targeting via Surface-Functionalized PEG-b-PPS Micelles for Acute Kidney Injury.

Boaz Y Bishop, Swagat H Sharma, Ratnakar Tiwari, Simseok A Yuk, Sultan Almunif, Susan E Quaggin, Evan A Scott, Pinelopi P Kapitsinou

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Boaz Y BishopDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University Chicago, IL.
Swagat H SharmaDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL.
Ratnakar TiwariDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University Chicago, IL.
Simseok A YukDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL.
Sultan AlmunifDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL.
Susan E QuagginDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University Chicago, IL.
Evan A ScottDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL.
Pinelopi P KapitsinouDepartment of Medicine and Division of Nephrology & Hypertension, Feinberg School of Medicine, Northwestern University Chicago, IL.

Funding

Therapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAPER, H WILLIAM · 2018 to 2022
$5.7M
Resource Development CoreU54DK137516 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Evan Alexander Scott · 2023 to 2026
$4.8M
Training Core for Chicago KUH FORWARDTL1DK132769 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Tamara Isakova · 2021 to 2026
$4.0M
Endothelial PHD2/HIF Axis in Ischemic Kidney Injury and InflammationR01DK115850 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Pinelopi P. Kapitsinou · 2018 to 2026
$3.5M
Compartment-specific manipulation of NAD+ to mitigate post-injury kidney disease.R21AG086806 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KAPITSINOU, PINELOPI P. · 2024 to 2024
$438k
NIA NIH HHS R21 AG086806NIDDK NIH HHS P30 DK114857NIDDK NIH HHS R01 DK115850NIDDK NIH HHS TL1 DK132769NIDDK NIH HHS U54 DK137516
6 · The paper itself

Abstract

While nanomedicine holds great promise for kidney disease, targeted delivery remains a major challenge. Most nanocarriers rely on passive accumulation or epithelial-specific ligands, limiting their utility in complex, inflamed renal environments. In acute kidney injury (AKI), inflammation and vascular dysfunction play central roles, yet targeting strategies beyond the tubule remain underexplored. Here, dual-ligand micelles are developed to enhance nanocarrier localization to the inflamed kidney by simultaneously engaging both organ- and injury-specific cues. Poly(ethylene glycol)-block-poly(propylene sulfide) (PEG-b-PPS) micelles were engineered to display two peptide ligands: CLPVASC, which preferentially distributes to the kidney, and CYNTTTHRC, which binds selectively to inflamed endothelium. These targeting motifs were incorporated via lipid-anchored peptide amphiphiles, enabling modular surface functionalization without disrupting micelle morphology, size, or charge. In vitro, dual-targeted micelles demonstrated enhanced uptake by human endothelial cells exposed to hypoxia-reoxygenation. In vivo, following unilateral renal ischemia-reperfusion injury (IRI) in mice, targeted micelles achieved selective accumulation in the injured kidney, outperforming both non-targeted controls and contralateral kidneys. Off-target distribution to liver, lung, and spleen was markedly reduced, confirming the spatial precision of the dual-ligand approach. This strategy offers a scalable, modular, and biologically informed platform for precision delivery in AKI and related inflammatory conditions.

Identifiers

PMID40791493
PMCPMC12338732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.